Mortimer G, Casey M
J Clin Pathol. 1981 Sep;34(9):958-62. doi: 10.1136/jcp.34.9.958.
A series of 25 cases of lung cancer are presented in which total (TAcP) and nonprostatic serum acid phosphatase (NPAcP) activities were measured. Of these cases, 36% had raised TAcP and NPAcP activities in their serum. However, the serum activities of TAcP and NPAcP did not correlate with either the presence of lung cancer nor with the morphological tumour type. This fact indicates that, despite isolated reports of raised serum acid phosphatase activities in cases of lung cancer, acid phosphatase is of no value as a marker for lung cancer. We sought alternative explanations for the raised TAcP and NPAcP activities observed in our series in the hope that this enzyme might prove useful as a marker for early metastatic disease in lung cancer patients. This possibility is not substantiated, and the findings are analyzed and discussed. It is tentatively suggested that raised NPAcP activities in patients with lung cancer may relate to haemostasis.
本文报告了25例肺癌患者，检测了其血清总酸性磷酸酶（TAcP）和非前列腺酸性磷酸酶（NPAcP）活性。其中，36%的患者血清TAcP和NPAcP活性升高。然而，TAcP和NPAcP的血清活性与肺癌的存在或肿瘤形态类型均无相关性。这一事实表明，尽管有个别报道称肺癌患者血清酸性磷酸酶活性升高，但酸性磷酸酶作为肺癌标志物并无价值。我们试图对本系列中观察到的TAcP和NPAcP活性升高寻找其他解释，希望这种酶可能被证明是肺癌患者早期转移疾病的有用标志物。但这一可能性未得到证实，并对研究结果进行了分析和讨论。初步认为，肺癌患者NPAcP活性升高可能与止血有关。
